Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-07-27

FDA Approved: MIRVASO — Supplemental Application (Galderma Laboratories, L.P.)

View source ↗

Summary

FDA approved a supplemental application for MIRVASO (brimonidine tartrate) submitted by Galderma Laboratories, L.P.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mirvaso (brimonidine tartrate)

Snippet

SUPPL AP for MIRVASO (BRIMONIDINE TARTRATE)